CL2018001258A1 - Métodos para tratar las condiciones asociadas con la activación del complemento dependiente de masp-2 - Google Patents

Métodos para tratar las condiciones asociadas con la activación del complemento dependiente de masp-2

Info

Publication number
CL2018001258A1
CL2018001258A1 CL2018001258A CL2018001258A CL2018001258A1 CL 2018001258 A1 CL2018001258 A1 CL 2018001258A1 CL 2018001258 A CL2018001258 A CL 2018001258A CL 2018001258 A CL2018001258 A CL 2018001258A CL 2018001258 A1 CL2018001258 A1 CL 2018001258A1
Authority
CL
Chile
Prior art keywords
masp
activation
methods
dependent complement
conditions associated
Prior art date
Application number
CL2018001258A
Other languages
English (en)
Inventor
Gregory A Demopulos
Thomas Dudler
Hans-Wilhelm Schwaeble
Original Assignee
Omeros Corp
Univ Leicester
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Omeros Corp, Univ Leicester filed Critical Omeros Corp
Publication of CL2018001258A1 publication Critical patent/CL2018001258A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21104—Mannan-binding lectin-associated serine protease-2 (3.4.21.104)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

EN UN ASPECTO, LA INVENCIÓN PROPORCIONA MÉTODOS PARA INHIBIR LOS EFECTOS DE LA ACTIVACIÓN DEL COMPLEMENTO DEPENDIENTE DE MASP-2 EN UN SUJETO HUMANO QUE PADECE TMA ASOCIADO CON TRASPLANTE DE CÉLULAS MADRE HEMATOPOYÉTICAS. LOS MÉTODOS COMPRENDEN LA ETAPA DE ADMINISTRAR, A UN SUJETO QUE LO NECESITE, UNA CANTIDAD DE UN AGENTE INHIBIDOR DE MASP-2 EFICAZ PARA INHIBIR LA ACTIVACIÓN DEL COMPLEMENTO DEPENDIENTE DE MASP-2.
CL2018001258A 2015-11-09 2018-05-09 Métodos para tratar las condiciones asociadas con la activación del complemento dependiente de masp-2 CL2018001258A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562252814P 2015-11-09 2015-11-09
US201662406726P 2016-10-11 2016-10-11

Publications (1)

Publication Number Publication Date
CL2018001258A1 true CL2018001258A1 (es) 2018-10-12

Family

ID=58691444

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2018001258A CL2018001258A1 (es) 2015-11-09 2018-05-09 Métodos para tratar las condiciones asociadas con la activación del complemento dependiente de masp-2

Country Status (20)

Country Link
US (2) US20170137537A1 (es)
EP (1) EP3373963A4 (es)
JP (2) JP6814802B2 (es)
KR (2) KR102277166B1 (es)
CN (2) CN117398458A (es)
AU (2) AU2016354117B2 (es)
BR (1) BR112018009311A8 (es)
CA (1) CA3004753C (es)
CL (1) CL2018001258A1 (es)
EA (1) EA201891132A1 (es)
GE (2) GEP20237574B (es)
IL (2) IL259225B (es)
MD (1) MD4685C1 (es)
MX (1) MX2018005165A (es)
MY (1) MY197758A (es)
NZ (1) NZ742987A (es)
PH (1) PH12018501009A1 (es)
SG (2) SG11201803834UA (es)
UA (1) UA124094C2 (es)
WO (1) WO2017083371A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101870915B1 (ko) 2011-04-08 2018-06-25 유니버시티 오브 레스터 Ｍａｓｐ-2 의존적 보체 활성화와 관련된 질병을 치료하는 방법
HUE051746T2 (hu) 2013-10-17 2021-03-29 Omeros Corp Eljárások MASP-2-függõ komplement aktiválással kapcsolatos állapotok kezelésére
JP2019524220A (ja) * 2016-07-06 2019-09-05 マイクロオプティクス インコーポレイテッド 緑内障治療装置および方法
JOP20170170B1 (ar) 2016-08-31 2022-09-15 Omeros Corp صيغ لجسم مضاد تثبيطية لـ masp-2 بتركيز عالي ولزوجة منخفضة وأطقم، وطرق
TWI818919B (zh) * 2017-08-15 2023-10-21 美商歐米諾斯公司 用於治療和／ 或預防與造血幹細胞移植有關的移植物抗宿主病和／ 或瀰漫性肺泡出血和／ 或靜脈閉塞性病的方法
RU2020111574A (ru) * 2017-08-25 2021-09-27 Омерос Корпорейшн Высококонцентрированные, маловязкие препараты ингибирующих masp-2 антител, наборы и способы лечения субъектов, страдающих атипическим гемолитическим синдромом
CN112638417A (zh) * 2018-06-22 2021-04-09 奥默罗斯公司 用于治疗各种血栓性疾病和病症的抑制masp-2的组合物和方法
JP2023504543A (ja) 2019-12-04 2023-02-03 オメロス コーポレーション Ｍａｓｐ－２阻害剤および使用方法
CN115052862A (zh) 2019-12-04 2022-09-13 奥默罗斯公司 Masp-2抑制剂和使用方法
US20210171461A1 (en) 2019-12-04 2021-06-10 Omeros Corporation Masp-2 inhibitors and methods of use
JP2023504544A (ja) 2019-12-04 2023-02-03 オメロス コーポレーション Ｍａｓｐ－２阻害剤および使用方法

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4394370A (en) 1981-09-21 1983-07-19 Jefferies Steven R Bone graft material for osseous defects and method of making same
US4526909A (en) 1984-01-09 1985-07-02 Regents Of The University Of California Polymethylmethacrylate delivery system for bone morphogenetic protein
US4563489A (en) 1984-02-10 1986-01-07 University Of California Biodegradable organic polymer delivery system for bone morphogenetic protein
JPH0662679B2 (ja) 1985-06-21 1994-08-17 新田ゼラチン株式会社 組織親和性コラ−ゲンとその製法
US5453566A (en) 1986-03-28 1995-09-26 Calgene, Inc. Antisense regulation of gene expression in plant/cells
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8822492D0 (en) 1988-09-24 1988-10-26 Considine J Apparatus for removing tumours from hollow organs of body
US5211657A (en) 1988-11-07 1993-05-18 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Laminin a chain deduced amino acid sequence, expression vectors and active synthetic peptides
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5549910A (en) 1989-03-31 1996-08-27 The Regents Of The University Of California Preparation of liposome and lipid complex compositions
DE69030172T2 (de) 1990-01-26 1997-06-19 Immunomedics Inc Impfstoffe gegen Krebs und Infektionskrankheiten
JP3218637B2 (ja) 1990-07-26 2001-10-15 大正製薬株式会社 安定なリポソーム水懸濁液
US5789573A (en) 1990-08-14 1998-08-04 Isis Pharmaceuticals, Inc. Antisense inhibition of ICAM-1, E-selectin, and CMV IE1/IE2
JP2958076B2 (ja) 1990-08-27 1999-10-06 株式会社ビタミン研究所 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法
IL108367A0 (en) 1993-01-27 1994-04-12 Hektoen Inst For Medical Resea Antisense polynzcleotide inhibition of human growth factor-sensitive cancer cells
US5801154A (en) 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein
US5856121A (en) 1994-02-24 1999-01-05 Case Western Reserve University Growth arrest homebox gene
US5741516A (en) 1994-06-20 1998-04-21 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
JPH10510540A (ja) 1994-12-12 1998-10-13 オメロス メディカル システムズ，インコーポレーテッド 灌注用溶液並びに疼痛、炎症及びけいれんの抑制法
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US5738868A (en) 1995-07-18 1998-04-14 Lipogenics Ltd. Liposome compositions and kits therefor
US5739119A (en) 1996-11-15 1998-04-14 Galli; Rachel L. Antisense oligonucleotides specific for the muscarinic type 2 acetylcholine receptor MRNA
KR20080099355A (ko) 1999-07-21 2008-11-12 오메로스 코포레이션 동통, 염증 및 연골 퇴화를 억제하기 위한 용액 및 억제방법
AU781805B2 (en) * 1999-08-13 2005-06-16 Brigham And Women's Hospital Inhibitors of the lectin complement pathway (LCP) and their use
US6649592B1 (en) 2000-01-14 2003-11-18 Science & Technology Corporation @ Unm Peptide inhibitors of LFA-1/ICAM-1 interaction
SG98393A1 (en) 2000-05-19 2003-09-19 Inst Materials Research & Eng Injectable drug delivery systems with cyclodextrin-polymer based hydrogels
MXPA04007124A (es) 2002-02-01 2004-10-29 Omeros Corp Composiciones y metodos para la inhibicion sistemica de la degradacion del cartilago.
ES2601143T3 (es) 2002-07-19 2017-02-14 Omeros Corporation Copolímeros tribloque biodegradables, métodos de síntesis de los mismos, e hidrogeles y biomateriales preparados a partir de los mismos
US7919094B2 (en) 2004-06-10 2011-04-05 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
KR101870915B1 (ko) * 2011-04-08 2018-06-25 유니버시티 오브 레스터 Ｍａｓｐ-2 의존적 보체 활성화와 관련된 질병을 치료하는 방법
US20150166676A1 (en) * 2011-04-08 2015-06-18 Omeros Corporation Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation
NZ629473A (en) * 2012-06-18 2017-02-24 Univ Leicester Compositions and methods of inhibiting masp-1 and/or masp-2 and/or masp-3 for the treatment of various diseases and disorders
WO2015039126A1 (en) * 2013-09-16 2015-03-19 Children hospital medical center Compositions and methods for treatment of hsct-associated thrombotic microangiopathy
HUE051746T2 (hu) * 2013-10-17 2021-03-29 Omeros Corp Eljárások MASP-2-függõ komplement aktiválással kapcsolatos állapotok kezelésére
KR102011118B1 (ko) * 2018-04-13 2019-08-14 김정범 개선된 스냅 단추

Also Published As

Publication number Publication date
IL295200A (en) 2022-10-01
SG10202011469UA (en) 2020-12-30
AU2020201500A1 (en) 2020-03-19
BR112018009311A2 (pt) 2018-11-06
BR112018009311A8 (pt) 2019-02-26
MD4685B1 (ro) 2020-03-31
US20210047433A1 (en) 2021-02-18
KR20180074789A (ko) 2018-07-03
CN108472347A (zh) 2018-08-31
JP2021063093A (ja) 2021-04-22
MD20180042A2 (ro) 2018-09-30
IL259225A (en) 2018-07-31
EA201891132A1 (ru) 2018-10-31
PH12018501009A1 (en) 2019-01-28
EP3373963A4 (en) 2019-07-10
KR20210090283A (ko) 2021-07-19
JP2018533592A (ja) 2018-11-15
CN108472347B (zh) 2023-09-05
KR102432062B1 (ko) 2022-08-12
GEP20247583B (en) 2024-01-10
UA124094C2 (uk) 2021-07-21
MD4685C1 (ro) 2020-12-31
US20170137537A1 (en) 2017-05-18
EP3373963A1 (en) 2018-09-19
MY197758A (en) 2023-07-13
MX2018005165A (es) 2020-11-11
CA3004753C (en) 2023-02-28
CA3004753A1 (en) 2017-05-18
JP6814802B2 (ja) 2021-01-20
WO2017083371A1 (en) 2017-05-18
AU2016354117A1 (en) 2018-05-10
NZ742987A (en) 2019-12-20
CN117398458A (zh) 2024-01-16
IL259225B (en) 2022-09-01
AU2016354117B2 (en) 2019-11-28
SG11201803834UA (en) 2018-06-28
GEP20237574B (en) 2023-12-25
KR102277166B1 (ko) 2021-07-15

Similar Documents

Publication Publication Date Title
CL2018001258A1 (es) Métodos para tratar las condiciones asociadas con la activación del complemento dependiente de masp-2
CL2018000429A1 (es) Moduladores de la expresión de kras
CL2018003213A1 (es) Inhibidores enzimáticos.
CL2019000511A1 (es) Inhibidores de procesos metabólicos celulares.
CR20150376A (es) Compuestos sustituidos de pirrolopirimidina, compuestos de los mismos y metodos de tratamiento con los mismos
ECSP17070399A (es) Anticuerpos contra icos
MX2021008044A (es) Metodos para el tratamiento de condiciones asociadas con la activacion del complemento dependiente de masp-2.
CY1120950T1 (el) Θεραπεια ινωσης
CL2017001188A1 (es) Métodos y formulaciones para tratar enfermedades vasculares de los ojos.
GT201700167A (es) Terapias de combinación para el tratamiento de cánceres.
CL2018001817A1 (es) Métodos para la inhibición de la fibrosis en un sujeto en necesidad de ellos
NI201600071A (es) Compuestos de inhibidor de autotaxina
MX2015016100A (es) Inhibidores de criopirina para prevenir y tratar la inflamacion.
CL2017001046A1 (es) Inhibidoes del bromodominio
CL2018000070A1 (es) Modulares de diaciglicerol aciltransderasa 2 (dgta2)
CL2017000416A1 (es) Métodos para tratar el mieloma múltiple con compuestos inmunomoduladores en combinación con anticuerpos
ECSP14030779A (es) Inhibidores del nampt
UY36014A (es) ?derivado de pirazol amida, composición farmacéutica y método para tratar o prevenir enfermedades autoinmunes, inflamatorias, metabólicas o cancerosas?.
CL2016000326A1 (es) Composiciones y método para tratar condiciones asociadas con el complemento
CL2019000304A1 (es) Fracciones de plasma en sangre como tratamiento para tratamientos cognitivos relacionados con el envejecimiento.
CL2016001076A1 (es) (aza) piridopirazolopirimidinonas e indazolopirimidinonas como inhibidores de fibrinolosis.
CR20150604A (es) Proceso para la preparación de eritrocitos cargados con una o más sustancias de interés farmacéutico y eritrocitos así obtenidos
NI201600070A (es) Inhibidores tetracíclicos de autotaxina
CL2019002574A1 (es) Moduladores de la expresión de pcsk9.
CO2017012645A2 (es) Agente antihipertensivo que comprende s-1-propenilcisteína o una sal del mismo como ingrediente activo